The AHA May 8 filed an amicus brief in the U.S. District Court for the District of Nebraska in defense of the state’s 340B contract pharmacy law prohibiting drug companies from denying hospitals the same 340B discounts for drugs dispensed at community pharmacies that would be provided via in-house pharmacies. The brief supports the state’s attempt to dismiss a case by AbbVie claiming that the federal law that created the 340B program preempts the state law.

The AHA has made similar filings in cases for multiple states. Joining the AHA in the Nebraska filing were 340B Health, the Nebraska Hospital Association and the American Society of Health-System Pharmacists. 

Related News Articles

Headline
The AHA May 1 expressed concerns (LINK) to the Centers for Medicare & Medicaid Services about the payment process established under the Medicare…
Headline
Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy, M.D., R-La., today released a report detailing findings from an investigation…
Headline
The AHA April 18 filed friend-of-the-court briefs in three cases in support of Louisiana's 340B contract pharmacy law that prohibits drug companies from…
Headline
A Minnesota state court April 15 dismissed a lawsuit filed by PhRMA challenging the state’s law protecting 340B pricing for contract pharmacy arrangements. The…
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription…
Headline
The Department of Health and Human Services said its decision to prevent drug companies from implementing a 340B rebate model “was within its statutory…